Menaquinone (vitamin K2) therapy for bronchial asthma. II. Clinical effect of menaquinone on bronchial asthma.
A series of 191 patients with bronchial asthma were treated with menaquinone for not less than one year to investigate the clinical effects of the drug. The clinical effect may be summarized as follows: 1) The therapy with menaquinone only gave an effective rate oo 90.9% (a markedly effective rate of 42.4%) in mild patients, an effective rate of 86.7% (a markedly effective rate of 30.0%) in moderate patients, and effective rate of 72.7% (a markedly effective rate of 27.3%) in severe patients; namely, considerably a high effective rate was attained by the therapy in the respective patients. 2) The therapy with menaquinone, in conjunction with hyposensitization therapy, gave an effective rate of 100% (a markedly effective rate of 33.3%). 3) The double blind study of the clinical effects of menaquinone revealed that placebo used in the study was effective on only 16.7% of the patients treated with it, and that the incidence of recurrence due to withdrawal of meaquinone therapy tended to be low in the patients treated with the drug for a long period of time.
D001249:Asthma / Q000188:drug therapy* / Q000628:therapy; D001379:Azathioprine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003888:Desensitization, Immunologic; D004338:Drug Combinations; D006046:Gold / Q000627:therapeutic use; D006632:Histamine / Q000627:therapeutic use; D006801:Humans; D015122:Mercaptopurine / Q000627:therapeutic use; D010919:Placebos; D014812:Vitamin K / Q000627:therapeutic use*; D005719:gamma-Globulins / Q000627:therapeutic use
D004338:Drug Combinations; D010919:Placebos; D005719:gamma-Globulins; D014812:Vitamin K; D006046:Gold; D006632:Histamine; D015122:Mercaptopurine; D001379:Azathioprine